📌 COMPOSITION

Each 1 g contains: Clobetasol propionate 0.5 mg.

📌 DESCRIPTION

Dermotop contains a medicine called clobetasol propionate, which belongs to the most potent class of topical corticosteroids group. Dermotop has anti‑inflammatory, antipruritic and vasoconstrictive properties; moreover, it helps to reduce swelling and irritation.

📌 INDICATIONS

• Psoriasis (excluding widespread plaque psoriasis).
• Recalcitrant eczemas.
• Lichen planus.
• Discoid lupus erythematosus and other skin conditions which do not respond satisfactorily to less active steroids.

📌 DOSAGE & ADMINISTRATION

• Apply Dermotop sparingly to the affected area once or twice daily. Treatment should not be continued for more than 4 weeks. If continuous treatment is necessary, a less potent preparation should be used. Allow adequate time for absorption after each application before applying an emollient.
• The maximum weekly dose should not exceed 50 g/week.

📌 RESTRICTIONS ON USE

Contraindications

• Hypersensitivity to clobetasol propionate.
• It could make the following skin problems worse: rosacea, acne vulgaris, perioral dermatitis, perianal and genital pruritus.
• Primary cutaneous viral infections (e.g., herpes simplex, chickenpox).
• The use of Dermotop skin preparations is not indicated in the treatment of primary infected skin lesions caused by infection with fungi or bacteria; dermatoses in children under one year of age, including dermatitis and napkin eruptions.

Precautions

• Topical steroids may be hazardous in psoriasis for a number of reasons, including rebound relapses, development of tolerance, risk of generalised pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin. If used in psoriasis, careful patient supervision is important.
• Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected. Any spread of infection requires withdrawal of topical corticosteroid therapy and systemic administration of antimicrobial agents.
• Long‑term continuous therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur.
• If used in childhood or on the face, courses should be limited if possible to five days. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as glaucoma might result.

Use in Pregnancy and Lactation

If you are pregnant or are breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

📌 SIDE EFFECTS

• Common: A feeling of burning, pain, irritation or itching where the cream is applied.
• Uncommon: Dilatation of superficial blood vessels and local atrophy.
• Very rare: Hypersensitivity reaction; features of hypercortisolism, pigmentation change, hypertrichosis, exacerbation of underlying symptoms, pustular psoriasis, rash, skin dryness and skin wrinkling.

📌 OVERDOSAGE

Acute overdosage is very unlikely to occur; however, in the case of overdosage, features of hypercortisolism may appear. In this situation, topical steroids should be discontinued gradually under medical supervision because of the risk of adrenal insufficiency.

📌 STORAGE INSTRUCTIONS

Store below 30°C.

📌 PHARMACEUTICAL FORMS

Dermotop Cream and Ointment: Tube 15 g.